High Response Rate With Neoadjuvant Anti-PD-1 in Localized dMMR Colorectal Cancer
Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients…
Browsing Tag
dMMR
Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition
CHICAGO -- Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced…
GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer
SAN FRANCISCO -- Research presented here at the Gastrointestinal Cancers Symposium (GICS) included promising data in…
FDA Grants Tissue-Agnostic Approval to Dostarlimab for dMMR Tumors
The FDA granted a fifth tissue-agnostic indication, expanding approved use of the PD-1…
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or…
Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe…